Robert Kilkuskie

Direktor/Vorstandsmitglied bei Michigan High Throughput Screening Center

Commercial Services

Profil

Robert Kilkuskie currently works at Michigan High Throughput Screening Center, as Executive Director from 2009 and National Institute of Health Policy, as Principal.

Aktive Positionen von Robert Kilkuskie

Unternehmen	Position	Beginn
Michigan High Throughput Screening Center Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties.	Direktor/Vorstandsmitglied	-
National Institute of Health Policy	Corporate Officer/Principal	30.04.2010

Alle aktiven Positionen von Robert Kilkuskie

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Robert Kilkuskie im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
National Institute of Health Policy
Michigan High Throughput Screening Center Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties.	Commercial Services